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ABSTRACT 
 
In New Brunswick (NB), Canada, the sea louse, Lepeophtheirus salmonis, poses an on-going 
management challenge to the health and productivity of commercially cultured Atlantic salmon, 
Salmo salar. While the in-feed medication, emamectin benzoate (SLICE® Merck, Canada) has 
been highly effective for many years, evidence of increased tolerance has been observed in the 
field since late 2008. Although bioassays on motile stages are a common tool to monitor sea lice 
sensitivity to emamectin benzoate in field collected sea lice, they require the collection of large 
numbers of sea lice due to inherent natural variability in the gender and stage response to 
chemotherapeutants. In addition, sensitive instruments such as EC50 analysis may be 
unnecessarily complex to characterise susceptibility subsequent to a significant observed decline 
in efficacy. This study proposes an adaptation of the traditional, dose-response format bioassay 
to a fixed-dose method. Analysis of 657 bioassays on pre-adult and adult stages of sea lice over 
the period 2008-2011, indicated a population of sea lice in NB with varying degrees of 
susceptibility to emamectin benzoate. A seasonal and spatial effect was observed in the 
robustness of genders and stages of sea lice, which suggest that mixing different genders and 
stages of lice within a single bioassay may result in pertinent information being overlooked. Poor 
survival of adult female lice in bioassays, particularly during May/June, indicates it may be 
prudent to consider excluding this stage from bioassays conducted at certain times of the year. 
This work demonstrates that fixed-dose bioassays can be a valuable technique in detecting 
reduced sensitivity in sea lice populations with varying degrees of susceptibility to emamectin 
benzoate treatments. 
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Introduction 
Emamectin benzoate (SLICE®) is an avermectin chemotherapeutant that is used as an in-feed 
treatment of sea lice, Lepeophtheirus salmonis on Atlantic salmon, Salmo salar, and has been 
used extensively in New Brunswick since the late 1990s initially through the Emergency Drug 
5HOHDVHSURJUDPPHRI+HDOWK&DQDGD¶V9HWHULQDU\'UXJV'LUHFWRUDWH, before receiving full 
approval for use in Canada in 2009.  The effectiveness of emamectin benzoate resulted in it 
becoming the preferred chemotherapeutant for control of sea lice in coastal finfish aquaculture 
operations in Atlantic Canada, and in other parts of the world over the last decade, often to the 
exclusion of other products.  It has been demonstrated that reliance on therapies with a single 
mode of action has proven to be a factor in the selection for resistance (Denholm, Devine, 
Horsberg, Sevetdal, Fallang, Nolan, & Powell, 2002) and indeed, decreasing sea lice sensitivity 
to emamectin benzoate has since been reported in Chile (Bravo, Sevatdal & Horsberg, 2008), 
Ireland (Hamish Rodgers, pers comm), Scotland (Lees, Baillie, Gettinby & Revie, 2008a), 
Norway (Pettersen, 2009; Horsberg, 2012), and Canada (Jones, Hammell, Dohoo & Revie, 
2012).  
 
Although published reports are limited, anecdotal evidence of a reduction in sensitivity of sea 
lice to emamectin benzoate in New Brunswick exists (Mark Moore, pers comm.; Chang, Page, 
Beattie & Hill, 2011) based on a reduction in the efficacy of this once highly effective 
chemotherapeutant in certain sea lice populations at marine aquaculture sites in the Bay of 
Fundy. In Canada, therapeutants for control of sea lice and similar ectoparasites on cultured fish 
which are administered externally by direct or indirect application are subject to the Pest Control 
Products and Food and Drug Acts, administered by the Pest Management Regulatory Authority 
(PMRA) and the Veterinary Drugs Directorate, respectively. Both these agencies suggest using 
therapeutants with different modes of action in rotation as a means of decreasing resistance 
pressure. Caution should, however, be exercised when attributing clinical treatment failures with 
emamectin benzoate to resistance development without considering other extenuating 
circumstances which can influence treatment outcome (Lees, Baillie, Gettinby & Revie, 2008b). 
Misdiagnosis of tolerance will negatively influence determination of the optimum dose sufficient 
to kill the maximum number of lice present but minimize toxicity to fish and the environment 
(Denholm et al., 2002).  For this reason, it is important to use laboratory-based assessment 
methods (e.g. bioassays) to identify changes in sea lice susceptibility to therapeutants. 
 
Bioassays are the conventional means by which insecticide resistance is detected. Over the past 
decade, bioassay protocols have been adapted for use as a common tool to monitor sea lice 
resistance to chemotherapeutants globally, including sensitivity to emamectin benzoate in 
laboratory-reared (Sevatdal & Horsberg, 2003; SEARCH Consortium 2006) and field collected 
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(Westcott, Stryhn, Burka & Hammell, 2008) sea lice. As expected, variations in bioassay 
methods exist between research groups (e.g. solvent used, doses tested, separation of sea lice by 
gender and stage for testing, statistical approach used to estimate effective concentration) 
(Sevatdal, Copley, Wallace, Jackson, & Horsberg, 2005; Westcott et al., 2008; Bravo et al., 
2008). While these protocols are appropriate and effective, they require the collection of large 
numbers of sea lice due to inherent natural variability in response to chemotherapeutants and 
differences in gender and stage response to treatment. In addition to the fact that not all stages of 
lice are readily available at all periods of the year, their collection is labour-intensive and thus 
costly. The adaptation of the traditional, dose-response format bioassay to one that significantly 
reduced the number of sea lice required to obtain reliable efficacy assessments is the focus of this 
paper. 
 
In addition to the costs and difficulties of collecting lice from the field, there is evidence that as 
WROHUDQFHGHYHORSVZLWKLQDVHDOLFHSRSXODWLRQLWDSSHDUVWRUHDFKD³WLSSLQJSRLQW´DIWHUZKLFK
it spreads rapidly through the remaining population of lice. This was seen in the results of 
clinical evaluations of tolerance to emamectin benzoate as measured by post-treatment efficacy 
in populations of lice on Scottish salmon farms (Lees et al, 2008a; 2008b). In these studies a 
gradual reduction in efficacy was observed between 2002 and 2005, before a sudden and 
dramatic drop in 2006, at which time approximately two-thirds of all treatments were deemed to 
be ineffective. Of particular interest in the context of the present study is the fact that a very 
similar situation appears to have prevailed in the New Brunswick salmon industry, albeit at a 
slightly later time period (Jones et al., 2012).  
 
The conceptual diagram shown in Figure 1 provides a representation of the situation that may 
arise with respect to sea lice tolerance to a given mode of action. During the initial use of a given 
product it can be expected that the compound will be maximally effective. Indeed, the curve 
shown accepts the argument that the maximum effectiveness will not be achieved until some 
point after initial introduction, as a consequence of the learning period associated with 
developing best practice on the part of the user. This situation can remain reasonably unchanged 
for some time, reflected in the graph by the maximum effectiveness plateau (MEP). Following 
this phase, there is likely to be a period of gradually reducing effectiveness XQWLODµWLSSLQJSRLQW¶
is reached after which, effectiveness declines rapidly. The length of time (i.e. the scale on the x-
axis) over which reasonable effectiveness can be maintained will, of course, vary by treatment 
compound and across situations. Factors including host density, mode of action, environmental 
conditions, e.g. area-wide flushing, and the relative density of farmed and wild salmonid hosts, 
may all have an impact on the trajectory of the effectiveness profile over time. 
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The purpose of introducing this concept in the current context is not to engage in speculation as 
to the relative importance of these various factors, but rather to illustrate where the various types 
RIELRDVVD\DUHOLNHO\WREHPRVWDSSURSULDWH,QWKHLQLWLDOVWDJHVRIDJLYHQSURGXFW¶VXVH
changes in effectiveness are likely to be modest and relatively sensitive tests are required to 
detect any change. During this phase it is recommended that traditional bioassays using the dose-
response format be used as they are more suited to picking up subtle changes in parasite response 
to chemical use ± as measured, for example, by changes in the value of EC50 estimates. Given the 
µnoise¶ associated with measurement in any natural/biological system, even these tests may not 
be sensitive enough to detect small changes in efficacy, but they should be able to demonstrate 
whether the chemotherapeutant is still relatively effective. However, once the tipping point has 
been reached, effectiveness begins to reduce so rapidly that less sensitive instruments can be 
used to detect such declines. This paper explores the utility of a fixed-dose emamectin benzoate 
bioassay in the context of the declining effectiveness of SLICE® to control sea lice populations 
across multiple aquaculture sites in New Brunswick.    
 
 
Figure 1 Schematic view of the typical scenario that might be observed as tolerance to a 
compound develops within an ectoparasitic population following multiple exposures to 
the compound 
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Materials and Methods 
 
Sea Lice Collections 
 
Motile stages of sea lice - adult females (AF), pre-adult males and adult males (PAM-AM) and 
pre-adult females (PAF) - were collected during 2008 to 2011 from 38 Atlantic salmon Salmo 
salar marine farm sites within the Bay of Fundy, New Brunswick, Canada, during routine 
harvests (i.e. market-sized fish that were not anaesthetized) or while routine sea lice counting 
was taking place on site (i.e. pre-market sized fish that were anaesthetized using tricaine 
methanesulfonate at a dose of approximately 100 mg l-1) (TMS, Syndel Laboratories). 
Collections occurred throughout the year. For the purposes of this study two seasons were 
considered, according to mean sea water temperatures. In the analysis, winter-spring is defined 
as January to June and summer-fall is defined as July to December. Mean (± sd) water 
temperatures were 4.6 (± 2.0) °C in winter-spring and 11.8 (± 2.3) °C in summer-fall. Based on 
distinctly separate hydrographics and geographical locations, the bay management areas (BMAs) 
were categorised into two main regions for analytical purposes: Region 1 - Campobello Island, 
Deer Island, Lime Kiln Bay and Passamaquoddy Bay; and Region 2 ± Grand Manan Island 
(Figure 2).  
 
Sea lice were gently removed from the salmon using forceps and placed into a sealed container 
containing seawater collected from the sea cage site. Battery operated air pumps were added to 
collection containers for aeration during transport and these were transported back to the 
laboratory in coolers containing ice packs. Sea lice were held overnight at 10-12°C in an 
incubator to allow them to acclimate prior to bioassay set-up the following morning.  
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Figure 2  Farm sites in the Bay of Fundy, New Brunswick where Sea Lice Counts and 
Collections were performed: Campobello Island (C), Deer Island (D), Passamaquoddy 
Bay (PB), Lime Kiln Bay (LK) and Grand Manan Island 
 
 
 
 
Bioassay Procedure 
 
A total of 657 bioassays were performed between 2008 and 2011 comprising 3,532 individual 
dishes (10 lice per dish), including three life stages (i.e. AF, PAM-AM and PAF). All bioassays 
were performed at the Atlantic Veterinary College, University of Prince Edward Island, using a 
standardized protocol. The same personnel conducted all trials. All bioassays were initiated 
within 24h of collection; sea lice have been found to be more robust after storage at 10°C with 
air pumps for 12 hours or more to recover from handling and transport (Westcott et al., 2008). A 
stock solution of emamectin benzoate was prepared for each bioassay by dissolving 5 mg of 
emamectin benzoate (PESTANAL7, Sigma-Aldrich, St. Louis, MO) in 50 ml methanol (or 25 ml 
of methanol + 25 ml de-ionized water when dilution was necessary).  This working solution was 
used to prepare experimental solutions of 400 ppb and 800 ppb emamectin benzoate. The 
concentrations of emamectin benzoate chosen for inclusion in the bioassays were based on 
preliminary bioassay results showing that a majority of lice died in this range when collected 
from a susceptible population (Westcott et al., 2008).  Control dishes (seawater only) were 
included in each trial. In all cases the experimental solutions used seawater taken from the same 
site from which the sea lice were collected. The exposure protocol involved exposing ten 
apparently healthy sea lice in glass Petri dishes to the treatment or control solutions; triplicate 
dishes of treatment and control were used.  The Petri dishes were incubated in a temperature-
controlled chamber at 10°C for an exposure period of 24 hours, as specified by Westcott et al. 
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(2008). All dishes were blinded as to treatment allocation. Following exposure, the condition 
(live, weak, moribund, or dead) of each sea louse was evaluated, according to an adopted set of 
bioassay response criteria (Westcott et al., 2008).  For the purposes of this study, evaluations of 
sea lice were aggregated into two groups: live (live, weak) and dead (moribund, dead). 
 
 
Statistical Analysis 
 
Descriptive statistics of the proportion of dead sea lice by trial, lice stage, and dose were 
tabulated. A random effects Poisson model was used to investigate the association between the 
expected count of dead lice and each of the predictors of interest after adding random effects for 
site and trial. The outcome variable was the number of dead lice per dish and the Poisson 
exposure was defined as the total number of lice per dish (n=10). The predictor variables were: 
region, year, stage of lice, dose of emamectin benzoate and season. The unconditional 
association between the outcome and each of the independent variables was examined at P<0.15. 
Significant variables were further included in a multivariable random effects Poisson regression 
model keeping only those variables which have a significant association with the outcome at P 
<0.05 (Dohoo, Martin & Stryhn, 2009). Two-way interactions between all significant predictors 
in the final main effects model were evaluated. The impact of the interaction terms on the 
proportion of dead lice were presented graphically. Mortality in the control group was modeled 
separately using the same predictors. All analyses were performed using Stata version 12 (Stata 
Corp., College Station, TX). 
   
 
Results 
 
In the bioassays performed over the period 2008 to 2011, there was considerable difference in 
the numbers of the different stages collected opportunistically in the field. Of the total number of 
bioassays, 14.5 % were performed using pre-adult females, compared with 35.0 % using pre-
adult and adult males and 50.5 % using adult females. For each bioassay conducted and each sea 
lice stage tested in the bioassay (i.e. adult females, pre-adult/adult males and pre-adult females) 
the proportion of dead sea lice was calculated (Table 1). Over the period 2008-2011, a total of 
657 bioassays were conducted on adult females, adult males, pre-adult males and pre-adult 
females.  
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Table 1  Frequency distribution of average trial mortality by dose & stage  
Dose N 
Percentile 
Mean Range 
10% 25% 50% 75% 90% 
Adult Female 
0 115 0.05 0.15 0.30 0.61 0.85 0.39 0-1 
400 110 0.29 0.45 0.70 0.90 0.99 0.66 0.03-1 
800 107 0.55 0.72 0.88 0.97 1 0.82 0.15-1 
Pre-Adult Male/Adult Male 
0 79 0 0 0.06 0.20 0.40 0.13 0-1 
400 76 0.08 0.14 0.27 0.54 0.80 0.36 0.05-1 
800 75 0.30 0.40 0.60 0.94 1 0.62 0.1-1 
Pre-Adult Female 
0 34 0 0.03 0.10 0.2 0.53 0.17 0-0.70 
400 31 0.29 0.33 0.44 0.70 0.95 0.52 0-1 
800 30 0.58 0.77 0.89 1 1 0.84 0.23-1 
 
The mean control mortality for adult female lice was 39%, which was much higher than either 
pre-adult males and adult males (13%) or pre-adult females (17%). All trials were included in the 
analysis. Excluding trials from the analysis based on a specific threshold for control mortality, 
for example > 20%, would add bias to the model by excluding trials which have a greater 
proportion of adult female lice. At the 400 ppb dose of emamectin benzoate, the proportion of 
dead lice was higher for pre-adult female and adult female lice compared to pre-adult male and 
adult male lice. Similar results were also found at the 800 ppb dose. As expected, there was an 
increase in the proportion of dead lice, for all stages, as the dose of emamectin benzoate 
increased.  
 
There was no difference in mortality of control lice between Regions 1 and 2, although overall, 
control mortality was higher in 2009-2011 compared to 2008. Figure 3 illustrates the predicted 
proportion of dead lice in the control group as a function of lice stage and time of year. 
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Figure 3  Predicted proportion of dead lice in the control group, by lice stage and month 
 
A higher proportion of dead lice were observed in control adult female lice compared to pre-
adult female, pre-adult male and adult male lice. An increase in control mortality was observed 
during May and June for all stages. Separate analyses (not shown) considering each lice stage in 
each of the four years (2008-2011) produced a similar trend. 
 
Table 2 describes the random effects Poisson model for the association between the number of 
dead lice exposed to 400 and 800 ppb emamectin benzoate and the different predictors.  
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Table 2  Random effects Poisson model for the association between the number of dead lice 
exposed to 400 and 800 ppb emamectin benzoate and different predictors. 
Covariate Coefficient Standard Error P - value 
Lower 95% 
Confidence 
Interval 
Upper 95 % 
Confidence 
Interval 
Region (reference = Region 1) 
Region 2  0.305 0.092 0.001 0.126 0.485 
Year (ref = 2008)      
2009 0.049 0.105 0.636 -0.155 0.254 
2010 0.153 0.102 0.135 -0.048 0.353 
2011 0.566 0.108 0.000 0.355 0.777 
Dose (reference = Control 0 ppb) 
400 ppb 1.317 0.064 0.000 1.190 1.443 
800 ppb 1.955 0.061 0.000 1.835 2.075 
Stage (reference = Pre-adult males-adult males) 
Adult females 0.972 0.057 0.000 0.861 1.083 
Pre-adult females 0.462 0.093 0.000 0.280 0.643 
SeasonÁ (reference = Summer-Fall) 
Winter-Spring 0.524 0.079 0.000 0.369 0.680 
Intercept 
-2.695 0.110 0.000 -2.910 -2.479 
Random part      
Site 0.013 0.009  0.003 0.051 
Trial 0.087 0.014  0.063 0.119 
Á6XPPHU-Fall (July ±December); Winter-Spring (January ± June) 
A higher number of dead lice were evident for Region 2 compared to Region 1. The expected 
number of dead lice was also higher for 2009-2011 compared to 2008, however, this effect was 
only significant for 2011. Dose was highly significant, with a higher dose being associated with 
an increase in mortality. Both pre-adult female and adult female lice stages exhibited higher 
mortality compared to pre-adult male and adult male lice. The expected number of dead lice was 
higher in the winter-spring period compared to the summer-fall period. Significant interactions 
between dose and stage of lice (Figure 4) and between dose and season (Figure 5) were 
observed.  
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Figure 4  Effect of interaction between dose and stage on the proportion of dead lice (95% 
confidence intervals shown) 
 
 
 
 
 
 
 
 
 
 
 
Mortality in pre-adult male and adult male lice was consistently lower than mortality in adult 
female or pre-adult female lice regardless of the dose used (Figure 4). Mortality in pre-adult 
female lice was significantly lower than adult female lice for the control dose only, whereas at 
the 400 and 800 ppb dose, mortality in female lice tended to be similar. 
 
 
Figure 5 illustrates a higher proportion of dead lice in winter-spring compared to summer-fall in 
the absence of emamectin benzoate exposure (control). At the 400 ppb dose, season is no longer 
significant. Furthermore, at the 800 ppb dose, a higher, but not significant, proportion of dead 
lice were observed in the summer-fall season. In the winter-spring season, distinctions between 
mortality at the 400 ppb and 800 ppb doses were less obvious. However, during the summer-fall 
season, the differences in mortality between the two doses were more distinguishable. The 
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distribution of variance in the final model indicates that most of the variation was attributed to 
between-trial variance, whereas site to site variation was very small.  
 
 
Figure 5  Effect of interaction between dose and season on the proportion of dead lice (95%  
confidence intervals shown) 
 
 
 
 
 
 
 
 
 
 
Discussion 
Regular bioassay monitoring using farm-collected lice supports field-based observations, which 
are typically VXEMHFWWRKLJKOHYHOVRIHFRORJLFDOµQRLVH¶ (Westcott et al., 2008). Several authors 
have reported increased tolerance to chemotherapeutants based on bioassay evidence (Roth, 
Richards, Dobson & Rae, 1996; Tully & McFadden, 2000; Sevatdal & Horsberg, 
2003; Sevatdal et al., 2005). Increased tolerance to emamectin benzoate has been described in 
Chile for Caligus rogercresseyi (Bravo et al., 2008) which the authors attributed 
to the extensive use of this compound in the local industry. They also noted that the product is 
often used at higher than recommended doses and using prolonged treatment regimes, and was 
preceded by the use of ivermectin for approximately 10 years. While Westcott et al. 
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(2008) observed no bioassay evidence of increased tolerance to emamectin benzoate 
in sea lice in the Bay of Fundy, Canada, for collections done prior to 2005, seasonal or 
temperature associated trends were noted. Lees et al. (2008a) also reported spatial variation in 
efficacy to emamectin benzoate and a decline over time using epidemiological modeling of pre-
 and post-treatment farm data in Scotland. In a subsequent study based on the same data set (Lees 
et al., 2008b), the authors indicated that emamectin benzoate treatments administered on Scottish 
salmon farms were approximately 11 times more likely to be ineffective in 2006 compared to 
2003 (their reference year). 
 
The classic EC50 approach to bioassay data analysis requires a minimum of six therapeutant 
doses and a large number of sea lice in order to generate reliable EC50 estimates (10 sea lice per 
Petri dish with at least 3 replicates per dose, for a total of 180 viable sea lice of a given stage per 
bioassay). There are a number of challenges in estimating EC50 values from bioassays involving 
field collected sea lice using the classic approach. These include, but are not limited to, inherent 
individual variability in response to test compounds making EC50 estimates unreliable, varying 
levels of sea lice exposure to chemotherapeutants used in aquaculture operations which may 
influence sea lice health and response in bioassays, different ages of sea lice collected, and the 
influence of season/temperature on sea lice viability. In addition, the varying availability of sea 
lice from season to season will limit the number of individuals available for use in bioassays at 
any given time. These factors have the potential to influence estimates of EC50 values such that 
they cannot be made with any confidence as a result of constraining the fit of the data with the 
assumptions of the probit model, resulting in unacceptably wide 95% confidence intervals or 
inestimable EC50 values.  This is a noted deficiency of the maximum likelihood or minimum chi-
square method for estimating ED50 values based on the probit or logit models (Hamilton, Russo, 
& Thurston, 1977; Sanathanan, Gade & Shipkowitz, 1987). Similar influences have been 
observed in bioassays on the cattle tick, Boophilus microplus (Jonsson, Miller, Finn, & George 
2003; Jonsson, Miller, & Robertson, 2007). 
 
In contrast, the fixed-dose method affords a number of advantages over the traditional EC50 
approach. For example, fewer sea lice are needed; two doses (control and chosen fixed-dose) 
with the same number of lice per dish and replicates might require, for example, only 60 viable 
sea lice per bioassay. A reduction in the number of doses tested also significantly simplifies the 
set-up of each bioassay experiment compared to traditional bioassays with multiple doses. In 
addition, statistical analysis of results can be simplified to a straightforward comparison of 
mortality for 2 groups. Finally, the use of a single emamectin benzoate concentration/dose 
should be sufficient to allow for discrimination between susceptible and resistant populations of 
sea lice in the field, thus allowing decisions around the use of emamectin benzoate on sites to be 
informed in a more efficient and practical manner. 
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There is evidence that the efficacy of emamectin benzoate in New Brunswick declined 
significantly in 2008 when compared to the previous three years (Jones et al., 2012). Anecdotal 
reports would VXJJHVWWKDWWKLVUHSUHVHQWHGWKHµWLSSLQJSRLQW¶IRUPDQ\VHDOLFHSRSXODWLRQVLQ
the region and we have contended that sensitive instruments such as EC50 analysis are not well-
suited for characterising susceptibility subsequent to such a decline. This challenge has also been 
observed in other parasite populations where drug-resistance management practices have a better 
chance of succeeding if resistance is detected when the allele conferring resistance is still at a 
low frequency in the population. Sensitive molecular assays which identify the operation of 
selection for drug resistance before treatment failure becomes clinically observable are valuable 
at this point in time. However, once the resistance allele reaches a sufficiently high frequency in 
the population, the rate of spread of drug resistance, and treatment failure, over time is highly 
nonlinear (Churcher & Basanez, 2009).  
 
Many pharmacokinetic studies in animals have identified gender-specific biological responses to 
therapeutic exposure (Czerniak, 2001;Umeh & Currier, 2006; McKellar & Gokbulut, 2011) and 
sea lice are no exception in this regard (Stone, Roy, Sutherland, Ferguson, Sommerville & Endris 
2002; Sevatdal & Horsberg, 2003; Sevatdal et al., 2005; Westcott, Revie, Giffin & Hammell, 
2010; Igboeli, Fast, Heumann & Burka, 2012). Female sea lice collected in this study 
demonstrate an increased susceptibility to emamectin benzoate under bioassay conditions 
compared with male sea lice. The reasons for this are unclear. Susceptibility was also observed 
to increase over time from 2008 to 2011, with lice becoming significantly more susceptible to 
emamectin benzoate in 2011. The reasons for this are also unclear but, in general, the robustness 
of the lice, particularly adult female lice stages, appeared to decline from 2008 to 2011, as 
illustrated by increasing numbers of dead adult female lice in the control dose. This could be 
speculated as being due to the treatment pressure of  emamectin benzoate use at increased doses 
as well as the use of other chemotherapeutants with possible temporal and environmental 
impacts on the overall robustness of the lice. Use of emamectin benzoate in eastern Canada was 
almost exclusive until 2009, at which time bath treatments were introduced due to observed 
treatment failures with emamectin benzoate. Azamethiphos (Salmosan®), hydrogen peroxide 
(Interox® Paramove®50) and Ivermectin, and for a short time, deltamethrin (AlphaMax), have 
subsequently been included in sea lice management practices. 
 
An apparent seasonal and spatial effect was observed in the robustness of genders and stages of 
sea lice included in emamectin benzoate field bioassays. Survival in all control groups was 
significantly lower in winter-spring, compared to survival in summer-fall. This was again, 
particularly noticeable for the adult females. Variation in water temperature has been identified 
as an influencing factor in treatment efficacy of emamectin benzoate (Westcott et al., 2008; Lees 
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et al., 2008a; 2008b). It has been suggested that adult female lice developing in summer-fall have 
a shorter generation time in warmer temperatures and, as such, the numbers are more likely to 
increase exponentially (Costello, 2006). Whether a more rapid development implies a more 
robust, emamectin benzoate tolerant louse is unknown, although it has been shown that parasites 
that have a high reproduction rate per individual female and a high rate of natural parasite 
turnover, can rapidly transmit resistance (Wolstenholme, Fairweather, Prichard, Samson-
Himmelstjerna & Sangster, 2004; Prichard, 2005). As noted by Sevatdal & Horsberg (2003), age 
and gender also influence sensitivity to pesticides. The poor survival of adult females in the 
bioassays performed in this study could also be due to age of females, since it is likely that the 
majority present in the early months of the year were overwintering females (Jacobsen & Gaard, 
1997; Heuch, Knutsen, Knutsen & Schram, 2002; Boxaspen, 2006). Body size of lice may 
influence the exposure and uptake of emamectin benzoate in an immersion bioassay and it is 
possible that the overwintered adult females were larger than summer generations (Costello, 
2006) although considerable variation in size has been reported depending on the source of the 
specimens (Pike & Wadsworth, 1999). No determination of age (young vs old) was made 
between the two halves of each year; all adult females in this study were simply categorized to 
this stage according to Johnson & Albright (1991). Given the poor survival of adult female lice 
during the first half of the year, particularly May/June, it may be prudent to consider not using 
this stage in bioassays conducted during that time of the year. Some authors have suggested 
using only pre-adult II and adult male sea lice stages, or 50% of each gender, as the standard 
method for conducting field bioassays or similar controlled sensitivity tests (Sevatdal & 
Horsberg, 2003; SEARCH Consortium, 2006). However, the observations reported here raise 
questions as to the advisability of mixing different genders and stages of lice within a single 
bioassay as pertinent information may be overlooked. 
 
It is known that sea lice abundance and susceptibility in other regions of the world vary by 
geopraphic location (Lees et al., 2008b). Similarly, in this study,  sea lice collected from Region 
2 (Grand Manan Island) appeared to be significantly more susceptible to emamectin benzoate 
than sea lice collected from Region 1 (Campobello and Deer Islands, Passamaquoddy Bay and 
Lime Kiln Bay).  Recently it has been demonstrated that densities of farmed salmonids 
surrounding individual farms have a strong effect on sea lice infection pressure as well as 
increasing efforts of chemotherapeutic control thereby enhancing the risk of the development and 
spread of treatment resistance (Jansen, Kristoffersen, Viljugreun, Jimenez, Aldrin & Stein, 
2012). The density of aquaculture sites in Region 1 over the period 2008-2011 was significantly 
higher than in Region 2 and, in terms of emamectin benzoate treatments, records for between 
2009 and 2011 indicate that significantly more treatments occurred in Region 1 compared with 
Region 2. It is possible that the increased density and treatment pressure in Region 1 contributed 
to the decrease in susceptibility of lice to emamectin benzoate during the period studied. 
16 
 
 
The value of the single fixed dose biossay lies in the ability to categorise results into meaningful 
interpretations regarding developing resistance for different stages of lice within the population. 
The population of sea lice in the Bay of Fundy comprises lice with varying degrees of 
susceptibility to emamectin benzoate. The development of a statistical model to assess survival at 
a single fixed dose permits health professionals and producers to identify significant changes in 
susceptibility and compare these results across the industry. This information is important in the 
management strategies implemented to control sea lice infestations on aquaculture sites as 
optimal strategies to control resistance situations will differ according to the situation.  
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